Daniel J. Drucker, M.D., a senior investigator at Sinai Health System’s Lunenfeld-Tanenbaum Research Institute and a professor of medicine at University of Toronto in Ontario, Canada, has been chosen as the 2019 Hamm Prize Laureate. The honour comes with a $250,000 award — the largest of its kind in the world – and will be awarded this fall by Harold Hamm Diabetes Center at the University of Oklahoma Health Sciences Center.
The Hamm Prize recognizes and encourages lasting advances in the field of diabetes research. It is awarded to an individual who has either demonstrated lifelong contributions to the field or realized a singular advance, especially in leading toward a cure.
“My hope in awarding this unprecedented international research prize is that we would ignite worldwide scientific interest and innovation to find a cure for diabetes in this generation,” said Harold Hamm, chairman and CEO of Continental Resources Inc., headquartered in Oklahoma City.
Hamm provided the endowment to establish the prize, following his lead gift in 2007 for the establishment of Harold Hamm Diabetes Center. His endowment of the prize provides for its awarding every other year in perpetuity. This endowment represents a unique private/public partnership using philanthropic dollars as a catalyst for desperately needed medical advances, which is especially beneficial in the current environment marked by declining federal funding for medical research.
“I am grateful to Mr. Hamm for his generosity and commitment to end the threat of diabetes. This award brings an international spotlight on research that is essential to address this disease and helps to attract top clinicians and researchers to Harold Hamm Diabetes Center on our OU Health Sciences Center campus,” said OU President James L. Gallogly.
Dr. Drucker’s pioneering diabetes research has focused on a group of hormones called incretins, which help the pancreas produce insulin to use the energy it receives from food. When working properly, incretins help the body to control blood glucose and insulin secretion, regulate appetite, control the absorption of nutrients from food and convert those nutrients to energy.
However, in Type 2 diabetes, an incretin called glucagon-like peptide 1 (GLP-1) is in short supply or is affected by a protein that makes it inactive. Dr. Drucker’s laboratory uncovered the pathways that led to the development of two drug therapies that mimic and enhance GLP-1 so it can work naturally.
“Dr. Drucker’s discoveries have been revolutionary in diabetes research,” said Jacob E. “Jed” Friedman, Ph.D., director of Harold Hamm Diabetes Center. “His dedication to this field has resulted in new treatments for millions of people around the world.”
Dr. Drucker began his career as a clinical endocrinologist but decided to focus on research when he recognized its potential to improve lives. He is a senior researcher at the Lunenfeld-Tanenbaum Research Institute at Sinai Health System in Toronto.
Dr. Drucker was chosen for the prize by an international jury of diabetes scientists who met in Oklahoma in April. Jury members are: George L. King, M.D., Harvard Medical School; Bruce A. Buckingham, M.D., Stanford University; Bernard Thorens, Ph.D., University of Lausanne, Switzerland; Jay S. Skyler, M.D., University of Miami; and Steven E. Kahn, M.B., Ch.B., University of Washington.
Dr. Skyler, who has known Dr. Drucker for many years, said he is driven not only to understand the basic biology of the body’s state during Type 2 diabetes, but to translate his discoveries into new therapies. Dr. Drucker is someone who is “totally dedicated to getting the correct answers and doing science the right way,” Dr. Skyler said.
“He is tenacious, and he has added more to our knowledge of this general space than anyone,” Dr. Skyler said. “He is truly an outstanding recipient of the Hamm Prize.”
“This honour bestowed upon my research group is further affirmation of the scientific excellence in metabolism research at the Lunenfeld-Tanenbaum Research Institute and the University of Toronto,” Dr. Drucker said. “Since 1921, and the discovery of insulin, Canadian scientists have continued to make important contributions to understanding the factors causing diabetes and the development of new diabetes medications. I am very pleased that the work of our group, including many students and postdoctoral fellows, that has developed over a period of 25 years from basic science discovery to clinical impact, has been highlighted for recognition by the Harold Hamm Diabetes Center.”
Dr. Drucker’s discoveries in the research laboratory are unique in that they have already been transformed into therapies to help patients with Type 2 diabetes live healthier and happier lives, Dr. Kahn said.
“From my perspective, Dan’s legacy is already here,” Dr. Kahn said. “The question is, ‘How much bigger will it get?’”
The 2019 Harold Hamm International Prize for Biomedical Research in Diabetes will be presented during the Connect + Cure Gala at the National Cowboy and Western Heritage Museum in Oklahoma City on October 22, 2019. The Connect + Cure Gala is a biennial gala to benefit the Harold Hamm Diabetes Center and to raise awareness of diabetes research, clinical care and prevention.
_________
About Harold Hamm Diabetes Center
Harold Hamm Diabetes Center is committed to curing diabetes and ending the diabetes pandemic in the 21st century. It is among the world’s largest and most comprehensive institutions of its kind, integrating top-flight academic research with clinical care and disease prevention. The center oversees the world’s top research prize in the diabetes field. It has facilities in Oklahoma City and Tulsa as well as affiliated sites across the state, including partnerships with Native American communities. An innovative range of services includes support groups, cooking classes, lifestyle-intervention programs, and a summer camp for children and teens. For more information, visit hammdiabetescenter.org.
About OU Medicine
OU Medicine — along with its academic partner, the University of Oklahoma Health Sciences Center — is the state’s only comprehensive academic health system of hospitals, clinics and centres of excellence. With 11,000 employees and more than 1,300 physicians and advanced practice providers, OU Medicine is home to Oklahoma’s largest physician network with a complete range of specialty care. OU Medicine serves Oklahoma and the region with the state’s only freestanding children’s hospital, the only National Cancer Institute-Designated Stephenson Cancer Center and Oklahoma’s flagship hospital, which serves as the state’s only Level 1 trauma center. OU Medicine’s mission is to lead healthcare in patient care, education and research. To learn more, visit oumedicine.com.
About Sinai Health System
Sinai Health System is comprised of Mount Sinai Hospital, Bridgepoint Active Healthcare, Lunenfeld-Tanenbaum Research Institute and Circle of Care. As an integrated health system, it delivers exceptional care from healthy beginnings to healthy aging, especially for people with specialized and complex health needs, in hospital, community and home. Sinai Health System discovers and translates scientific breakthroughs, develops practical health solutions, educates future clinical and scientific leaders and leads efforts to eliminate health inequities. Its Lunenfeld-Tanenbaum Research Institute ranks in the top ten biomedical research institutes in the world. Sinai Health System is a full affiliate of the University of Toronto. www.sinaihealthsystem.ca
—————
For more information or to arrange an interview, please contact:
Janessa Bishop
Manager, Communications and Marketing
Sinai Health Foundation
416 586-4800 ext. 8454
[email protected]
Discover important information about student and learning programs and the resources we provide.
The future of discovery, clinical translation, and care at Sinai Health is set to scale new heights with life-changing innovation.
